DRYTEC
LOE ApproachingNDAINTRAVENOUS, ORALSOLUTION
Approved
Nov 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DRYTEC is an intravenous and oral solution approved in 1976 by GE HealthCare as an NDA product. The mechanism of action and specific indications are not publicly detailed in available data, limiting characterization of its therapeutic role. It represents a mature, legacy pharmaceutical asset in the diagnostic or specialized therapy space.
LOE Approaching
With LOE approaching and zero linked job openings, DRYTEC is likely a divested or minimal-investment asset with limited career development trajectory for commercial teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DRYTEC is not actively recruiting and offers extremely limited career development opportunities given its mature lifecycle stage and approaching loss of exclusivity. Professionals should expect minimal team size, flat or declining responsibilities, and limited visibility within parent organization GE HealthCare's portfolio.
Company
Worked on DRYTEC at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.